[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fondazione Policlinico Universitario Campus Bio-Medico\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":462},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,47,72,98,131,154,181,209,240,266,288,307,336,360,387,413,441],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645305","noninvasive-brain-stimulation-for-cervical-dystonia-100645305",false,"NCT07681284","Noninvasive Brain Stimulation for Cervical Dystonia","The Effect of Noninvasive Brain Stimulation on Symptoms of Cervical Dystonia","NetworkStim","Inclusion Criteria\n\n* Aged between 18 and 85 years\n* Diagnosis of idiopathic cervical dystonia made by an expert physician\n* Last botulinum toxin injection administered at least two months before the start of participation in the study (Albanese, Abbruzzese et al. 2015)\n\nExclusion Criteria\n\n* Head or neck trauma occurring less than 12 months before the onset of dystonia\n* Acquired dystonia (e.g., drug-induced, brain lesions or trauma)\n* History of major psychiatric disorders (e.g., bipolar disorder, schizophrenia, obsessive-compulsive disorder)\n* History of neurological diseases other than CD (e.g., epilepsy, Parkinson's disease)\n* Other contraindications for TMS or brain MRI (e.g., metal in the head)\n* Pregnant or breastfeeding women\n* History of substance abuse or dependence","ALL","18 Years","85 Years",{"count":21,"type":22},26,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary aim of this study is to assess whether continuous theta-burst stimulation (cTBS) can be helpful in reducing symptoms of idiopathic cervical dystonia. This will be a parallel-group, randomised, sham-controlled, double blind clinical trial. Patients and investigators measuring patient symptoms clinical scales will be blinded from allocation group, investigators delivering the intervention will not be blinded, as this is not feasible. Real cTBS will be compared to sham cTBS, with patients allocated to these two groups with a 1:1 recruitment ratio.\n\nBilateral cTBS will be delivered four times daily, over eight days, for a total of 32 bilateral cTBS sessions. The primary outcome is the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). This will be administered at T1 (pre-cTBS), T2 (day 10, following days 2-9 where patients received the intervention), T3 (2 weeks post the final session of cTBS), and T4 (4-5 weeks post the final session of cTBS).\n\nSecondary outcomes will be the TWSTRS subscales (severity, disability, pain), Quality of Life scale, Global dystonia severity rating scale (GDS), Fahn Tolosa Marin (FTM) modified (to include only questions relevant to head\u002Fneck tremor) tremor scale, kinematic data of patient's movement patterns, motor evoked potentials (MEPs), and resting-state fMRI data (fMRI).",[28],"Cervical Dystonia",[30,31,32,33],"Cervical dystonia","Transcranial magnetic stimulation","Somatosensory cortex","Continuous theta-burst stimulation","NOT_YET_RECRUITING","2026-06-26",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":22},"2026-07-06",{"date":42,"type":22},"2028-05-06",{"name":44,"class":45},"Fondazione Policlinico Universitario Campus Bio-Medico","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100641695","biophotonic-nanoparticle-enabled-laser-blood-test-for-early-detection-of-pancreatic-cancer-100641695","NCT07659639","Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer","LASERBLOOD","\\*\\*Inclusion criteria for patients with PDAC and IPMN:\\*\\*\n\n* No history of prior neoplastic diseases;\n* Adequate renal and hepatic function;\n* No hematologic disorders;\n* Age ≥ 18 years;\n* No active infections;\n* Written informed consent.\n\n\\*\\*Exclusion criteria:\\*\\*\n\n* Severe pre-existing medical conditions, such as serious illnesses or other medical conditions that could negatively affect study outcomes or pose a high risk to the patient's health;\n* Ongoing therapies that could interfere with the study or alter the results.",true,{"count":56,"type":22},400,[25],"LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm \\[IPMN\\] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.",[60,61,62],"Diabetes","IPMN, Pancreatic","PDAC - Pancreatic Ductal Adenocarcinoma","RECRUITING","2026-06-16",{"date":66,"type":38},"2026-06-22",{"date":68,"type":38},"2025-09-01",{"date":70,"type":22},"2029-08",{"name":44,"class":45},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100602125","low-impact-laparoscopy-in-bariatric-surgery-100602125","NCT07119437","Low Impact Laparoscopy In Bariatric Surgery","Low Impact Laparoscopy In Bariatric Surgery- A Monocentric Randomised Trial Comparing Low-Pressure Pneumoperitoneum Plus Microsurgery Versus Standard Laparoscopy","LILYBET","Inclusion Criteria:\n\n* Age between 18 years-old and 65 years-old\n* BMI (Body Mass Index) \\>35 Kg\u002Fm2 and \\\u003C 45 Kg\u002Fm2;\n* Patients candidate to sleeve gastrectomy\n\nExclusion Criteria:\n\n* Patients with neurological and\u002For psychiatric disorders\n* Patients with Chronic Pain Syndrome\n* Patients with a history of surgical procedures using a laparotomic approach in the upper abdominal quadrants","65 Years",{"count":82,"type":22},128,[25],"The goal of this clinical trial is to learn if low pressure pneumoperitoneum and small incisions (low impact laparoscopy, LIL) works to reduce pain and improve pulmonary function in patients underwent to bariatric surgery.\n\nIt will also learn about the safety and patients' satisfaction of the procedure. The main questions it aims to answer are:\n\nDoes LIL lower post surgical pain and improve pulmonary function? Is LIL safe for obese patients? Researchers will compare LIL to standard laparoscopy performing sleeve gastrectomy in patients with obesity.\n\nParticipants will:\n\nbe randomised to LIL group or standard laparoscopy. After the operation the researchers will evaluate the pain and the efficiency of lung ventilation at pre-established intervals. after 3 months the patients will complete a questionnaire on aesthetic satisfaction and overall satisfaction.",[86],"Obesity, Morbid",[88,89,90],"obesity","low impact laparoscopy","sleeve gastrectomy",{"date":92,"type":38},"2026-06-18",{"date":94,"type":38},"2025-02-04",{"date":96,"type":22},"2026-10-04",{"name":44,"class":45},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":46},"100643010","tl1a-inhibition-in-systemic-sclerosis-related-skin-fibrosis-and-immunological-alterations-a-proof-of-concept-in-vitro-study-fibrostop-100643010","NCT07642297","TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP)","The Potential Pharmacological Role of the TNF-Like Ligand 1A (TL1A) Inhibition in Modulating Systemic Sclerosis (SSc)-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept, In Vitro, Study","FIBROSTOP","Inclusion Criteria:\n\nFor both SSc and healthy control populations:\n\n* Signed written informed consent\n* Age ≥18 years at the time of consent\n\nFor SSc population only:\n\n* Diagnosis of SSc according to ACR\u002FEULAR 2013 classification criteria\n* Diffuse cutaneous SSc subtype (LeRoy et al., 1988)\n* Disease onset (defined as the first non-Raynaud symptom) within 5 years prior to recruitment\n* No new initiation of immunosuppressive therapy (including methotrexate, mycophenolate mofetil, cyclophosphamide, rituximab, tocilizumab, or prednisone \\>20 mg\u002Fday) within the 2 months preceding recruitment\n* Ongoing immunosuppressive therapy must be at a stable dose for at least 1 month prior to enrollment\n\nExclusion Criteria:\n\n* Coexisting active or treated skin diseases (e.g., atopic dermatitis), except for SSc\n* Diagnosis of other systemic autoimmune rheumatic diseases, including overlap syndromes (e.g., SSc + dermatomyositis)\n* History or current signs\u002Fsymptoms of severe or uncontrolled non-rheumatic diseases\n* Active malignancy or history of malignancy within the previous 5 years (except adequately treated non-melanoma skin cancer or in situ cervical carcinoma)\n* Chronic or recurrent infections, including viral hepatitis B\u002FC, HIV, or untreated tuberculosis\n* Severe active infection or major surgery within 8 weeks before enrollment\n* Non-serious skin infections within 8 weeks before enrollment\n* Limited cutaneous SSc or SSc sine scleroderma\n* SSc patients unable to undergo therapeutic stabilization due to severe organ complications\n* Pregnancy or lactation\n* Inability to provide informed consent",{"count":107,"type":22},20,"OBSERVATIONAL","Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by microvascular injury, immune activation, and progressive fibrosis of the skin and internal organs. Diffuse cutaneous SSc (dcSSc), particularly in its early phase, is associated with aggressive fibrotic evolution and high morbidity. Despite advances in immunomodulatory therapy, no treatment has proven capable of consistently halting or reversing fibrosis, highlighting the need for new mechanistic targets.\n\nTL1A (TNF-like ligand 1A) is a cytokine of the TNF superfamily expressed by endothelial and immune cells, which interacts with death receptor 3 (DR3) to regulate immune activation, endothelial dysfunction, and tissue remodeling. Elevated TL1A levels have been observed in SSc patients and correlate with disease activity. TL1A has also been shown to promote lung fibrosis in preclinical models.\n\nThe FIBROSTOP study is a proof-of-concept, in vitro, interventional study on biological samples aimed at elucidating the immunological and fibrotic mechanisms regulated by TL1A, and at assessing whether TL1A inhibition can reverse pathogenic processes in SSc.\n\nTen (n=10) patients with early diffuse cutaneous SSc and ten (n=10) age- and sex-matched healthy controls will be enrolled at a single center (Fondazione Policlinico Universitario Campus Bio-Medico, Rome). Each participant will undergo a single visit (T0) involving peripheral blood sampling and skin biopsy. No follow-up visits are planned.\n\nThe study pursues three co-primary objectives: (1) evaluating the role of TL1A and its inhibition in modulating T lymphocyte activity; (2) assessing the effects of TL1A and its inhibition on endothelial cell activation and function; (3) investigating the impact of TL1A and its inhibition on fibrotic remodeling in ex vivo SSc skin cultures using single-cell RNA sequencing.\n\nThe findings may inform future targeted antifibrotic interventions in SSc and other fibrotic diseases.",[111,112,113],"Systemic Sclerosis (SSc)","Diffuse Cutaneous Systemic Sclerosis","Skin Fibrosis",[115,116,117,118,119,120,121,122],"TL1A","TNF-like ligand 1A","DR3","Fibrosis","Scleroderma","T lymphocytes","Endothelial cells","skin biopsy","2026-06-04",{"date":125,"type":38},"2026-06-11",{"date":127,"type":22},"2026-09-01",{"date":129,"type":22},"2028-09-01",{"name":44,"class":45},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":139,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":46},"100562844","effects-of-a-telerehabilitation-intervention-in-the-management-of-complications-after-breast-cancer-surgery-100562844","NCT06608446","Effects of a Telerehabilitation Intervention in the Management of Complications After Breast Cancer Surgery","Effects of a Telerehabilitation Intervention in the Management of Complications After Breast Cancer Surgery: Randomized Controlled Trial","LINFO","Inclusion Criteria:\n\n* diagnosis of breast cancer\n* Having undergone quadrantectomy or mastectomy surgery\n* Age \\> 18 years\n* Signature of informed consent\n\nExclusion Criteria:\n\n* Neurological deficits with sensorimotor impairment of the upper limb\n* Cognitive deficits that prevent the completion of questionnaires (MMSE\\>24)","FEMALE",{"count":141,"type":22},155,[25],"The most common complaints after breast surgery are postoperative pain reported in up to 68% of patients, musculoskeletal problems in the shoulder and functional limitations in up to 59% of patients after mastectomy and quadrantectomy, reduction in range of motion ( ROM) in 24-53% and strength deficit.\n\nThe study aims to verify the effectiveness of a telerehabilitation treatment in terms of prevention of possible complications following breast cancer surgery.\n\nPrimary objective: to examine whether the group of patients undergoing rehabilitation surgery in the immediate post-operative period shows a reduction in the onset of complications compared to the group of patients who followed standard procedures.\n\nSecondary objective: to study any preoperative prognostic factors for the onset of complications, to study the effectiveness of the rehabilitation treatment in terms of reduction of painful symptoms, improvement of joint ROM, muscle strength and perceived quality of life.",[145],"Breast Neoplasms","2026-04-16",{"date":148,"type":38},"2026-04-21",{"date":150,"type":38},"2023-05-15",{"date":152,"type":22},"2026-07-30",{"name":44,"class":45},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},"100577376","virtual-reality-for-shoulder-rehabilitation-100577376","NCT06797492","Virtual Reality for Shoulder Rehabilitation","Virtual Reality for Shoulder Rehabilitation: New Approaches and Applications in Orthopedics","REVISA","Inclusion Criteria:\n\n* Patients with shoulder musculoskeletal disorders\n* Patients aged 18-75 years\n* Patients who have signed informed consent\n\nExclusion Criteria:\n\n* Patients with insufficient cognitive and language functions to follow instructions provided by clinicians and\u002For experimenters involved in the project\n* Patients who do exhibit impediments that could hinder the use of VR devices","75 Years",{"count":164,"type":22},50,[25],"Goal: The clinical investigation involves the evaluation of the usability level of the VR system, sense of presence, and co-presence during the execution of various rehabilitation exercises through specific questionnaires.\n\nParticipant Population: The study will enroll 50 patients with shoulder musculoskeletal disorders will be enrolled\n\nMain Questions:\n\n* How does the integration of Virtual Reality (VR) in rehabilitation programs impact the usability of the system for patients with shoulder musculoskeletal disorders?\n* To what extent does the sense of presence experienced by patients using VR systems influence their motivation and adherence to rehabilitation exercises?\n* How do patients with shoulder musculoskeletal disorders perceive the co-presence in VR rehabilitation scenarios, and how does it affect their overall treatment experience?\n\nParticipant Tasks:\n\n* Shoulder Physical Examination\n* Instructions to the patient on exercises to be performed using Oculus and selection of customizable settings on the VR app\n* Execution of the protocol developed for shoulder rehabilitation in a virtual environment\n* Evaluation of the usability of the VR system, sense of presence, and co-presence through different validated scales",[168],"Shoulder Musculoskeletal Disorders",[170,171,172],"Musculoskeletal disorders","shoulder rehabilitation","virtual reality","2026-03-02",{"date":175,"type":38},"2026-03-04",{"date":68,"type":38},{"date":178,"type":22},"2027-12",{"name":44,"class":45},2,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":46},"100564859","an-artificial-intelligence-based-approach-in-total-knee-arthroplasty-from-inflammatory-responses-to-personalized-medicine-100564859","NCT06634654","An Artificial Intelligence-based Approach in Total Knee Arthroplasty: From Inflammatory Responses to Personalized Medicine","AI-TKA","Inclusion Criteria:\n\n1. Symptomatic, end-stage knee osteoarthritis\n2. Ligaments functionally intact\n3. Age: older than18 years old\n\nExclusion Criteria:\n\n1. Neurological or other conditions affecting patients ability to join walking trials\n2. Inflammatory or infectious arthritis\n3. Previous articular fracture or knee surgery (excluding knee arthroscopy and meniscal surgery)\n4. Active tumors or pregnancy.",{"count":189,"type":22},197,[25],"Goal: The goal of this interventional study is to understand how multimodal preoperative data can predict outcomes after Total Knee Arthroplasty (TKA) and improve personalized medicine practices.\n\nParticipant Population: The study will enroll 197 patients suffering from symptomatic, end-stage knee osteoarthritis, who are above 18 years old and have functionally intact ligaments.\n\nMain Questions:\n\n* Can multimodal preoperative data, genetic predisposition, and psycho-behavioral characteristics predict outcomes after TKA?\n* Can AI models effectively use this data to customize prostheses and surgical interventions, and predict patient outcomes? Comparison Group Information (If applicable): Not specified in the provided details.\n\nParticipant Tasks:\n\n* Undergo TKA as per the normal clinical routine.\n* Participate in pre- and post-surgical follow-ups including:\n* Clinical-functional assessments.\n* Administration of clinical scores.\n* Collection of biological samples.\n* Biomechanical analysis using a stereophotogrammetric system.\n* Provide data for the comprehensive multimodal indexed database.",[193],"Knee Osteoarthritis",[195,196,197,198,199,200,201,202,193],"Artificial Intelligence","Total Knee Arthroplasty","Biomechanics","Orthopaedic surgery","Alarmins","Oxidative Stress","Cytokine","Knee Inflammation",{"date":175,"type":38},{"date":205,"type":38},"2024-10-14",{"date":207,"type":22},"2029-12",{"name":44,"class":45},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":217,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":4},"100618869","association-of-vagus-nerve-stimulation-and-treadmill-training-for-gait-rehabilitation-in-de-novo-parkinsons-disease-100618869","NCT07337226","Association of VAgus Nerve Stimulation and Treadmill Training for GAit Rehabilitation in DE Novo Parkinson's Disease","Association of VAgus Nerve Stimulation and Treadmill Training for GAit Rehabilitation in DE Novo Parkinson's Disease (AVANTGARDE-PD)","AVANTGARDE-PD","Inclusion Criteria:\n\n* Idiopathic PD diagnosis within 6 months, confirmed by neurologist specialized in Parkinson's disease and movement disorders;\n* Ability to walking independently for at least 10 meters unassisted;\n* Age included between 50 and 80;\n* MMSE \\> 24;\n* On stable therapy for at least 1 month prior to the experiment.\n\nExclusion Criteria:\n\n* Clinical and radiological red flags for atypical, vascular parkinsonism or alternative diagnosis (e.g., normal pressure hydrocephalus);\n* Levodopa equivalent daily dose \\> 300 mg;\n* Any contraindication for taVNS (e.g., ear lesions, auditory prosthesis)\n* Any contraindication for MRI (e.g., non compatible pacemakers or prosthesis, claustrophobic subjects);\n* Concomitant neurological, orthopedic or active medical\u002Foncological condition that would affect participating to the study;\n* Attempting to other neurorehabilitation programs within 3 months.","50 Years","80 Years",{"count":220,"type":22},60,[25],"The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) can improve gait and brain function in people with diagnosis of idiopathic Parkinson's disease (PD) within 6 months. It will also help researchers learn about the safety and biological effects of taVNS when used together with physical therapy.\n\nThe main questions it aims to answer are:\n\n* Does taVNS paired with physical therapy improve walking speed and gait performance in people with PD?\n* Does taVNS change brain activity or breain perfusion related to movement?\n* Does taVNS reduce markers of inflammation and neurodegeneration in blood and saliva? Researchers will compare active taVNS to sham (placebo) stimulation to see if active taVNS works better when paired with physical therapy.\n\nParticipants will:\n\n* Attend 12 rehabilitation sessions over 4 weeks (three per week)\n* Receive either active or sham taVNS during each session while doing treadmill and conventional physical therapy\n* Undergo gait and cognitive testing, MRI scans, and blood and saliva collection before and after treatment\n* Return for a follow-up visit four weeks after therapy to check how long the effects last",[224],"Idiopathic Parkinson's Disease (PD)",[226,227,228,229,230,231],"Parkinson's disease","Vagus nerve stimulation","non invasive brain stimulation","treadmill training","freezing of gait","rehabilitation","2026-01-04",{"date":234,"type":38},"2026-01-13",{"date":236,"type":22},"2026-01",{"date":238,"type":22},"2027-10",{"name":44,"class":45},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":139,"minAge":18,"maxAge":217,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":46},"100594622","dose-escalated-concomitant-boost-radiotherapy-for-early-breast-cancer-100594622","NCT07021846","Dose Escalated Concomitant Boost Radiotherapy for Early Breast Cancer","Hypofractionated Radiotherapy With Dose Escalated Concomitant Boost for Breast Cancer: a Phase 2 Trial","DEBoRa","Inclusion Criteria:\n\n* histologically proven breast cancer who have undergone conservative surgery\n* at least 3 inserted clips\n* age: from 18 years old to 50 years\n* at least one of the following risk factors: N1 disease, LVI, extensive intraductal component (\\>25%), close margins (\\\u003C4 mm), non-hormone-sensitive disease, grading 3\n* ECOG performance status \\\u003C 2\n* adequate bone marrow (haemoglobin concentration \\> 8 g\u002Fdl, white blood cell count \\> 3000\u002Fmm3, platelet count \\> 75000).\n\nExclusion Criteria:\n\n* Previous chest radiation treatment\n* Bilateral breast cancer\n* Neoadjuvant chemotherapy\n* BMI \\> 35\n* Collagen diseases\n* Pregnancy or breastfeeding",{"count":249,"type":22},132,[25],"The goal of this prospective, single-arm, phase II, non-randomized trial is to evaluate an hypofractionation schedule with high dose simultaneous integrated tumor bed boost in early breast cancer patients.\n\nThe main question\\[s\\] it aims to answer are:\n\n* evaluate the rate of all grades of radiation-induced fibrosis at 4 years.\n* evaluate poor\u002Ffair cosmesis rate Participants will be treated with hypofractionated radiotherapy (RT) to whole breast with a dose of 40.05 Gy in 15 fractions (2.67 Gy\u002Fdie) and a concomitant tumor bed dose of 52.5 Gy (3.5 gy\u002Fdie)",[253],"Breast Cancer",[255,256,257],"tumor bed boost","radiotherapy","hypofractionation","2025-06-11",{"date":260,"type":38},"2025-06-15",{"date":262,"type":38},"2020-03-12",{"date":264,"type":22},"2030-03",{"name":44,"class":45},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":46},"100594627","concomitant-radiotherapy-and-new-drugs-in-metastatic-breast-cancer-100594627","NCT07021911","Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer","COMBaRT","Inclusion Criteria:\n\n* Patients suffering from stage IV breast cancer\n* Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors)\n* Candidates for radiation treatment (both palliative and curative).\n\nExclusion Criteria:\n\n* Previous radiation treatment on the same site\n* Absolute contraindications to radiotherapy\n* Systemic treatment administered as part of a clinical trial",{"count":274,"type":22},300,"The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).",[253,277],"Radiotherapy; Complications",[279,256,280,281],"breast cancer","stereotactic radiotherapy (SABR)","side effects",{"date":260,"type":38},{"date":284,"type":38},"2023-05-17",{"date":286,"type":22},"2029-05-17",{"name":44,"class":45},{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":306},"100595182","improving-the-perception-of-stress-and-mutuality-in-caregivers-mi-dear-study-of-migraine-patients-with-depressive-symptoms-treated-with-fremanezumab-a-study-to-evaluate-whether-fremanezumab-reduces-the-impact-on-caregivers-and-increases-couple-reciprocity-100595182","NCT07029126","Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity","Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Prospective Real-life Observational Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity","Inclusion Criteria:\n\nPATIENTS\n\n* Adult patients, male or female\n* Diagnosis of migraine, with or without aura, or chronic migraine, according to the International Classification of Headaches (ICHD-3.)\n* Diagnosis of migraine with onset at an age of less than 50 years\n* Depressive symptoms in patients defined as a Patient Health Questionnaire PHQ-9 scale score ≥5\n* Complete details of migraine history and frequency of monthly migraine days in the past month\n* clinical indication to start fremanezumab therapy to prevent migraine in patients naïve to monoclonal antibodies targeting the CGRP pathway\n* In case of migraine preventive therapy and concomitant antidepressants, stability for at least 8 weeks prior to enrollment.\n* Presence of a caregiver (see definition below) of the patient\n* 80% compliance with diary and ability to complete the scale to provide written informed consent.\n\nINFORMAL CAREGIVERS:\n\n* Adult subjects, male or female.\n* Informal caregiver is defined as a person--spouse\u002Fpartner, parent, child\u002Fchild, sibling--who cares for the migraine patient, sharing the same household and performing various functions, from basic daily needs to socio-economic activities)\n* RSS score ≥ 1\n* 80% compliance with completion scale ability to provide written informed consent\n\nExclusion Criteria:\n\nPatients:\n\n* Patients without a caregiver\n* Contraindications or lack of indication to fremanezumab\n* The patient has clinically significant hematological, cardiac, renal, endocrine, pulmonary, gastrointestinal, genitourinary, neurologic, hepatic, ocular disease, or complications of an infection, at the discretion of the investigator\n* Patient with a clinical history of a severe or uncontrolled psychiatric disorder (bipolar disorders, schizophrenia, psychosis), at the discretion of the investigator, that would likely interfere with full participation in the study\n* Patient participating in another study at the same time as enrollment in the current study\n\nInformal Caregivers:\n\n* History of migraine.\n* History of major depressive disorder and severe or uncontrolled psychiatric disorder (bipolar disorders, schizophrenia, psychosis), at the discretion of the investigator, that would likely interfere with full participation in the study\n* The caregiver has clinically significant hematological, cardiac, renal, endocrine, pulmonary, gastrointestinal, genitourinary, neurologic, hepatic, ocular disease, or complications of an infection at the discretion of the investigator.",{"count":274,"type":22},"To evaluate the reduction of emotional burden (measured by Relative Stress Scale-RSS) of caregivers of migraine patients with Depressive Symptoms after 6 months after the first injection of fremanezumab.",[298],"Migraine",{"date":300,"type":38},"2025-06-19",{"date":302,"type":38},"2024-10-03",{"date":304,"type":22},"2026-03-30",{"name":44,"class":45},10,{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":319,"conditions":320,"keywords":323,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":46},"100444354","phase-2-efficacy-of-intradiscal-injection-of-autologous-bm-msc-in-subjects-with-chronic-lbp-due-to-multilevel-lumbar-idd-100444354","NCT05066334","Efficacy of Intradiscal Injection of Autologous BM-MSC in Subjects With Chronic LBP Due to Multilevel Lumbar IDD","Intervertebral Disc Regeneration Mediated by Autologous Mesenchymal Stem\u002FStromal Cells Intradiscal Injection: a Phase IIB Randomized Clinical Trial - DREAM Trial","DREAM","Inclusion Criteria:\n\n* Signed informed consent.\n* Symptomatic chronic LBP due to moderate IDD (modified Pfirrmann score 3-4, Griffith score 3-7) at max.3 levels of the lumbar spine unresponsive to conservative treatment, physical and medical for at least 6 months. Physical treatment includes physiotherapy. Medical treatments includes nonsteroidal anti-inflammatory drugs (NSAID), paracetamol, opioids and myorelaxant.\n* Annulus fibrosus intact, demonstrated by MRI.\n* Pain baseline \\> 40 mm on VAS (0- 100).\n* NSAID washout of at least 2 days before screening.\n* Painkillers washout of at least 24 hours before screening.\n* For females of childbearing potential, a negative pregnancy test must be documented at Screening.\n* Men and women should use effective contraception during treatment and for at least 24 months after BM-MSC discontinuation. As a precautionary measure, breast-feeding should be discontinued during treatment with BM-MSC and should not be restarted after discontinuation of BM-MSC.\n\nExclusion Criteria:\n\n* Congenital or acquired diseases leading to spine deformations that may upset cell application (scoliosis, isthmus lesion, sacralization and hemisacralization, degenerative spondylolisthesis).\n* Spinal segmental instability assessed by dynamic X-Ray.\n* Symptomatic facet joints syndrome on MRI (facet joints hyperintensity and hypertrophy evaluated at coronal T2 weighted MRI).\n* Prior to the screening visit, has received:\n* Oral corticosteroid therapy within the previous 3 months, OR\n* Intramuscular, intravenous or epidural corticosteroid therapy within the previous 3 months\n* Presence of a 4th level with symptomatic IDD (modified Pfirrmann score 3-4, Griffith score 3-7) in the lumbar spine.\n* Spinal canal stenosis (Schizas score \\> B).\n* History of spinal infection.\n* Lumbar disc herniation and sciatica.\n* Endplate abnormality such as Schmorl's Nodes.\n* Previous discal puncture or previous spine surgery.\n* IDD with Modic II and III changes on MRI images.\n* Patients not eligible to the intravertebral disc surgery.\n* Patients who have the risk to undergo a surgery in the next 6 months.\n* Patients with local infusion device\u002Fdevices for corticosteroids.\n* Obesity with body mass index (BMI in Kg\u002Fsize in m\\^2) greater than 35 (obesity grade II).\n* Participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study.\n* Abnormal blood tests: hepatic (alanine amino transferase \\[ALT\\] and\u002For aspartate aminotransferase \\[AST\\] \\> 1.5 × upper limit of normal \\[ULN\\]), renal, pancreatic or biliary disease, blood coagulation disorders, anemia or platelet count of \\\u003C 100 × 10\\^9\u002FL.\n* Pregnant or lactating women, or premenopausal women not using an acceptable form of birth control, are ineligible for inclusion. Contraception will be maintained during treatment and until the end of relevant systemic exposure. Additional pregnancy testing will be performed at the end of relevant systemic exposure. The patients will be required to use contraception from initial treatment administration until 24 months after the last dose of study drug.\n* In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is strongly recommended.\n* Positive serology for following infection: Syphilis, HIV, Hepatitis B, or C.\n* Contraindication to MRI assessed by the investigator.\n* Intolerance or allergy to local anaesthesia.\n* Any history of Cancer or immunodeficiency disease.\n* Previous transplantation.",{"count":316,"type":22},52,[318],"PHASE2","DREAM is a phase II B efficacy monocentric, prospective, randomized, controlled double blinded trial, comparing intra-discal autologous adult bone marrow mesenchymal stem cells (BM-MSC) therapy and sham treated controls in subjects with chronic (\\> 6 months) Low Back Pain (LBP) due to lumbar multilevel (max. 3 levels) intervertebral disc degeneration (IDD) unresponsive to conventional therapy.\n\nDuration of the recruitment period has been estimated to be 12 months. The efficacy of intradiscal injection of autologous BM-MSC in reducing chronic LBP due to multilevel lumbar IDD will be evaluated after 24 months in terms of pain relief (VAS), functionality (ODI) and quality of life (SF36).",[321,322],"Intervertebral Disc Degeneration","Chronic Low-back Pain",[324,325,321,326,327],"Low Back Pain","Spine","Mesenchymal Stem Cells","Bone Marrow","2025-05-21",{"date":330,"type":38},"2025-05-25",{"date":332,"type":38},"2021-03-22",{"date":334,"type":22},"2025-10-31",{"name":44,"class":45},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":46},"100590980","phase-4-potential-role-of-guselkumab-in-modulating-pain-perception-and-related-gene-pathways-a-proof-of-concept-study-100590980","NCT06974474","Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.","Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study","GUPAIN","Inclusion Criteria:\n\n* A man or a woman at least 18 and no more than 80 years of age;\n* Have a diagnosis of psoriatic arthritis (PsA) for at least 6 months the enrolment and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening;\n* Inadequate response or intolerance of standard treatment (namely, methotrexate and\u002For TNF inhibitors);\n* At least 3 months of non-biologic DMARDs (limited to methotrexate ≤25 mg\u002Fweek, sulfasalazine ≤3 g\u002Fday, hydroxychloroquine ≤400 mg\u002Fday, and leflunomide ≤20mg\u002Fday) or at least 4 weeks of NSDAIDs for psoriatic arthritis;\n* Patient eligible for Guselkumab (both monotherapy or combination therapy with methotrexate) treatment according to international recommendations, national and regional regulatory authorities, and EMA datasheet;\n* VAS pain major than 15 mm at the enrolment;\n* DAPSA major than 14 at the enrolment;\n* Have at least 1 of the PsA subsets: oligoarticular or polyarticular PsA subset, distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, spondylitis with peripheral arthritis;\n* Peripheral tender joints ≥ 1\n* Peripheral swollen joints ≥ 1\n* C-reactive protein ≥ 0.3 mg\u002FdL\n* Involvement (namely, swollen joint) of wrists or knees;\n* Subjects naïve to bDMARDs or previously treated with up to 2 anti-tumor necrosis factor (TNFα) agents, discontinued for lack of benefit to an anti-TNFα therapy, as assessed by the treating physician, after at least 12 weeks of etanercept, adalimumab, golimumab, or certolizumab pegol therapy (or biosimilar) and\u002For at least a 14-week dosage regimen (i.e., at least 4 doses) of infliximab (or biosimilar). Documented lack of benefit may include inadequate improvement in joint counts, physical function, or disease activity; Intolerance to an anti-TNFα biologic therapy, as assessed by the treating physician, to etanercept, adalimumab, golimumab, certolizumab pegol, or infliximab (or biosimilars); If no intolerance or lack of benefit, the reason for discontinuation must be documented;\n* If currently using non-biologic DMARDs (limited to methotrexate \\[MTX\\], sulfasalazine \\[SSZ\\], hydroxychloroquine \\[HCQ\\], or leflunomide \\[LEF\\]), subjects should have started treatment at least 3 months and the dose must be stable for at least 4 weeks before the first administration of study agent and should have no serious toxic side effects attributable to the non-biologic DMARD. If currently not using a MTX, SSZ, or HCQ, must have not received for at least 4 weeks before the first administration of study agent. If currently not using LEF, must not have received for at least 12 weeks before the first administration of study agent. If using MTX, the route of administration and dose must be stable and the dose must be ≤25 mg\u002Fweek. If receiving SSZ, the dose must be ≤ 3g\u002Fday. If receiving HCQ, the dose must be ≤400 mg\u002Fday. If receiving LEF, the dose must be ≤20 mg\u002Fday.\n* If currently using NSAIDs or other analgesics for PsA, subjects must be on a stable dose for at least 2 weeks before the first administration of study agent. If currently not using NSAIDs or other analgesics for PsA, must not have received NSAIDs or other analgesics for PsA within 2 weeks before the first administration of study agent;\n* Are willing to refrain from the use of complementary therapies for PsA or psoriasis including ayurvedic medicine, traditional Taiwanese, Korean, or Chinese medications, and acupuncture within 2 weeks before the first study agent administration and through Week 52;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of fibromyalgia according to ACR 2016 criteria;\n* Subjects with inflammatory diseases that might confound the evaluations of benefit of Guselkumab therapy, including but not limited to RA, axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease;\n* Patients who received more than 2 anti-TNFα agents; - Has received an anti-TNF agent within the following timeframes: Infliximab (or its biosimilars) or golimumab (intravenous) within 8 weeks before the first administration Guselkumab; Golimumab (subcutaneous), adalimumab (or its biosimilars) or certolizumab pegol within 6 weeks before the first administration of study agent; Etanercept (or its biosimilars) within 4 weeks before the first administration of study agent;\n* Has previously been treated with Guselkumab; - Diagnosis of psychiatric disorder according to DSM-V; - Pregnancy or lactation;\n* Systemic or intra-articular glucocorticoids in the last 3 months;\n* Has previously received any biologic treatment (other than anti-TNFα agents), including, but not limited to ustekinumab, abatacept, secukinumab, tildrakizumab, ixekizumab, brodalumab, risankizumab, or other investigative biologic treatment;\n* Has previously received tofacitinib, baricitinib, filgotinib, peficitinib (ASP015K), decernotinib (VX-509), or any other Janus kinase (JAK) inhibitor, as well as apremilast;\n* Has previously received any systemic immunosuppressants (e.g., azathioprine, cyclosporine, 6-thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study agent;\n* Has received non-biologic DMARDs (other than MTX, SSZ, HCQ, LEF) including, but not limited to chloroquine, gold preparations, and penicillamine within 4 weeks before the first administration of study agent;\n* Is currently receiving 2 or more allowed non-biologic DMARDs at baseline;\n* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of PsA), genitourinary, or metabolic disturbances;\n* Has unstable cardiovascular disease, defined as a recent clinical deterioration (e.g., unstable angina, rapid atrial fibrillation, or transient ischemic attack) in the last 3 months prior to screening or a cardiac hospitalization within the last 3 months prior to screening;\n* Currently has a malignancy or has a history of malignancy within 5 years before screening (with the exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study agent administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first Guselkumab administration);\n* Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance; or signs and symptoms suggestive of possible lymphoproliferative diseases, such as lymphadenopathy or splenomegaly;\n* Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (e.g., bronchiectasis), recurrent urinary tract infection (e.g., recurrent pyelonephritis or chronic nonremitting cystitis), fungal infection (e.g., mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers;\n* Has a transplanted organ (with exception of a corneal transplant \\>3 months before the first administration of the study agent);\n* Has a history of an infected joint prosthesis, or has ever received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced;\n* Has or has had a serious infection (e.g., sepsis, pneumonia, or pyelonephritis) or has been hospitalized or received IV antibiotics for an infection within 2 months before screening;\n* Has or has had a herpes zoster infection within 2 months before screening;\n* Is pregnant, nursing, or planning a pregnancy (both men and women) within 12 weeks after receiving the last administration of the study agent;\n* Has received, or is expected to receive, any live virus or bacterial vaccination within 3 months before the first administration of the study agent;\n* Has had a BCG vaccination within 12 months of screening;\n* Has known intolerance or hypersensitivity to any biologic medication, or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies, or antibody fragments;\n* Subject has known allergies, hypersensitivity, or intolerance to Guselkumab or its excipients;\n* Has a history of active granulomatous infection, including histoplasmosis or coccidioidomycosis, before screening;\n* Has a chest radiograph within 3 months prior to the first administration of the study agent that shows an abnormality suggestive of a malignancy, significant cardiovascular or pulmonary disease, or current active infection, including TB;\n* Has ever had a nontuberculous mycobacterial infection or opportunistic infection (e.g., cytomegalovirus, pneumocystosis, aspergillosis);\n* Is infected with human immunodeficiency virus (HIV, a confirmed positive serology for HIV antibody);\n* Tests positive for hepatitis B virus (HBV) infection at screening; - Is seropositive for antibodies to hepatitis C virus (HCV) at screening, unless the subject had 2 negative HCV ribonucleic acid (RNA) test results at least 6 months apart prior to screening and has a third negative HCV RNA test result at screening;\n* Has had major surgery (e.g., requiring general anesthesia and hospitalization) within 8 weeks before the screening, or will not have fully recovered from such surgery, or has such major surgery planned during the time the subject is expected to participate in the study; NOTE: Subjects with planned surgical procedures to be conducted under local anesthesia may participate.",{"count":21,"type":22},[346],"PHASE4","Psoriatic arthritis (PsA) is a chronic musculoskeletal disease that affects 0.1%-1% of the general population and about 20% of patients with psoriasis. Patients with PsA have a multifaceted pain experience, which depends on various factors, including joint inflammation, as well as peripheral and central pain sensitization. Although chronic pain is the most common symptom of PsA, few is known about the mechanisms driving it. From this point of view, the interactions between immune cells and nociceptors in the context of inflammation-related pain are emerging as a hot topic. Many studies suggested that IL-23\u002FIL-17 pathway may play a pivotal role in this regard. This is consistent with data currently available regarding Guselkumab in PsA. Indeed, according to DISCOVER 1 and DISCOVER 2, two randomized phase III trials, patients receiving Guselkumab achieved, among others, minimal disease activity state, significant improvement in the SF-36 physical component score, and visual analog scale of pain. This study proposal aims to evaluate the potential role of Guselkumab in modulating pain perception in PsA patients from a molecular, cellular, and electrophysiological point of view.",[349],"Psoriasis Arthritis",[351],"Guselkumab","2025-05-07",{"date":354,"type":38},"2025-05-16",{"date":356,"type":38},"2024-06-18",{"date":358,"type":22},"2027-05-27",{"name":44,"class":45},{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":386},"100583235","soft-tissue-sarcoma-motor-performance-robotic-rehabilitation-nutrition-and-quality-of-life-100583235","NCT06873685","Soft Tissue Sarcoma: Motor Performance, Robotic Rehabilitation, Nutrition, and Quality of Life","Soft Tissue Sarcoma: Instrumented Evaluation of Motor Performance and Impact of Robotic Rehabilitation, Nutrition and Quality of Life Assessment (START-RUN1)","START-RUN1","Inclusion Criteria:\n\n1. patient with primary and localized STS who is a candidate for limb-sparing surgery or retroperitoneal multivisceral resection (including partial or complete resection of the iliopsoas muscle with functional loss and potential femoral nerve involvement) with curative intent;\n2. age 18 years or older.\n\nExclusion Criteria:\n\n1. recurrent tumors;\n2. metastatic disease;\n3. candidate for palliative and non-radical surgery;\n4. refusal to sign informed consent;\n5. Pregnant or breastfeeding women at the time of screening.",{"count":369,"type":22},120,[25],"Soft tissue sarcomas are a group of rare and heterogeneous tumors. Surgery is the mainstay of treatment and microscopic negative margins need to be achieved to improve disease local control. We designed this prospective study to evaluate the main features of motor impairment and the impact of tailored robotic rehabilitation techniques in patients treated for localized soft tissue sarcoma (surgery alone, or surgery + radiation or radiochemotherapy). Specific patients' motor strategies will be quantitatively measured through a biomechanical assessment, including the analysis of joint kinematics, and muscle activity timing patterns. Considering the influence of motor impairment after demolitive surgery, a major interest of this study will be focused on nutrition and Quality of life which will be prospectively evaluated by specific questionnaires at different time points.",[373],"Sarcoma, Soft Tissue",[231,375,376,377],"nutrition","quality of life","instrumented assessment of motor performance","2025-03-19",{"date":380,"type":38},"2025-03-21",{"date":382,"type":38},"2025-03-13",{"date":384,"type":22},"2026-08-31",{"name":44,"class":45},3,{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":46},"100566001","identify-the-most-effective-rehabilitation-method-between-a-treatment-with-a-sensorized-treadmill-walker-view-and-a-treatment-with-conventional-group-therapy-in-balance-disorders-and-the-use-of-artificial-intelligence-to-identify-predictive-indices-to-prevent-falls-and-diagnose-promptly-the-risk-100566001","NCT06649500","Identify the Most Effective Rehabilitation Method Between a Treatment with a Sensorized Treadmill (Walker View) and a Treatment with Conventional Group Therapy in Balance Disorders and the Use of Artificial Intelligence to Identify Predictive Indices to Prevent Falls and Diagnose Promptly the Risk","Comparison Between Treatment with Sensorized Treadmill and Conventional Therapy in Balance Disorders and Use of Artificial Intelligence in Identifying Predictive and Prognostic Indices of the Risk of Falling in Balance Disorders in Adult-elderly Subjects","UAI","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Consent to participate in the study\n* Positive history of balance disorders\n* Absence of cognitive deficits (MMSE ≥ 24)\n* Tinetti \\< 25\n\nExclusion Criteria:\n\n* Clinical pictures associated with musculoskeletal, cardiovascular, cerebrovascular, neuro-psychic problems and post-surgical outcomes that make the planned evaluation tests unfeasible.\n* Inability to carry out a walking test.\n* History of more than one fall in the last six months.\n* Subjects who have not expressed informed consent to participate in the study.",{"count":396,"type":22},108,[25],"Falls in the elderly are one of the main sources of disability and hospitalization, with a significant impact on quality of life and social and healthcare costs. Falls represent a significant health concern for people over 60 years old. Numerous studies have shown that falls cause serious health consequences. Around 30% of people over the age of 60 experience a fall during the year.\n\nAccording to the impact falls have, the investigators decided to analyze the effectiveness of training on a Walker View sensorized treadmill, with the possibility of exercises for coordination and balance, compared to training with a conventional group therapy, in order to understand the best training to reduce the risk of falling and observe the possible improvements in daily life activities.\n\nSo the study aims to identify the most effective rehabilitation method between a treatment with a sensorized treadmill (Walker View) and a conventional group therapy in balance disorders.\n\nThe study also aims to identify predictive indices, with the use of Artificial Intelligence, that can contribute to the prevention and diagnosis of balance disorders in a short time and prevent falls in the elderly.",[400,401,402,403,404,405],"Balance Disorders","Rehabilitation","Falls","Falls Prevention","Artificial Intelligence (AI)","Elderly (people Aged 65 or More)","2025-03-17",{"date":378,"type":38},{"date":409,"type":38},"2024-12-04",{"date":411,"type":22},"2026-06",{"name":44,"class":45},{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":424,"conditions":425,"keywords":426,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":440},"100557406","onabotulinumtoxin-a-in-chronic-migraine-patients-with-short-or-long-disease-history-the-bach-study-100557406","NCT06537700","OnaBotulinumtoxin-A in Chronic Migraine Patients With Short or Long Disease History (the BACH Study)","OnaBotulinumtoxin-A Effectiveness Evaluation in Chronic Migraine Patients With Short or Long Disease History: an Italian Multicentric Study (the BACH Study)","BACH","Inclusion Criteria:\n\n* Age between 18 and 70 years-old\n* Chronic Migraine defined according to 1.3 ICHD-3\n* Informed consent\n\nExclusion Criteria:\n\n* secondary headache\n* Onabotulinumtoxin-A in the previous 3 months\n* pregnancy or breastfeeding\n* detoxification protocol for Medication Overuse Headache in the last 6 months","70 Years",{"count":423,"type":22},115,"The goal of this observational prospective multicentric study, 12 months duration is to investigate whether the history of Chronic Migraine and, more precisely, its duration for over or less than 10 years, can predict OBT-A treatment effectiveness.\n\nSince CM patients may have a complex psychopathological profile and psychiatric symptoms represent a bad prognostic factor influencing treatment effectiveness, the present study will also aim at evaluating if the psychopathological profile of the enrolled patients may influence the outcome.",[298],[427,428,429,430,431],"Chronic migraine","OnabotulinumtoxinA","Migraine prevention","Disease duration","Psychiatric comorbidities","2024-09-17",{"date":434,"type":38},"2024-09-19",{"date":436,"type":38},"2024-01-01",{"date":438,"type":22},"2025-12-31",{"name":44,"class":45},6,{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":448,"targetDuration":450,"studyType":108,"phases":4,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":46},"100537777","clinical-evaluation-motor-performance-and-quality-of-life-in-patients-affected-by-soft-tissue-sarcomas-undergoing-surgical-treatment-observational-study-100537777","NCT06282237","Clinical Evaluation, Motor Performance and Quality of Life in Patients Affected by Soft Tissue Sarcomas, Undergoing Surgical Treatment: Observational Study","1206","Inclusion Criteria:\n\n\\- Adult patients affected by primary localized soft tissue sarcoma, candidate to limb\u002Ftrunk surgery with wide excision or retroperitoneal resection (including resection of the iliopsoas muscle with possible damage to the femoral nerve) with curative intent.\n\nExclusion Criteria:\n\n* Patients with recurrent tumors;\n* patients with metastatic disease;\n* patients with palliative surgery;\n* patients with amputations.",{"count":449,"type":22},13,"6 Months","The main aim of the study is evaluate quality of life and motor performance of patients with soft tissue sarcomas undergoing surgical treatment and post-operative rehabilitation treatment.\n\nPrimary objectives:\n\n* Identification of clinical characteristics and motor damage after surgery for soft tissue sarcomas;\n* Impact of perioperative treatments and surgery on the quality of life of patients with soft tissue sarcomas;\n* Impact of post-operative rehabilitation treatment on quality of life and recovery of motor activity The primary endpoint will be the improvement in the Toronto Extremity Salvage Score (TESS) between T1 (post-surgery) and T3 (at the end of rehabilitation treatment).\n\nSecondary endpoints will be:\n\n1\\. the evolution over the various timepoints of the selected rating scales (Toronto Extremity Salvage Score, Musculoskeletal Tumor Society Rating Scale, Numerical Rating Scale, Brief Pain Questionnaire, Douleur Neuropathique en 4 Questions, Leeds Assessment of Neuropathic Symptoms and Signs Scale, European Organization for Research and Treatment of Cancer, Quality-of-Life Questionnaire (QLQ)-C30, Short Form Health Survey 36);\n\n• The change in walking performance before and after the rehabilitation treatment.",[453],"Sarcoma","2024-02-27",{"date":456,"type":38},"2024-02-28",{"date":458,"type":38},"2023-07-01",{"date":460,"type":22},"2026-07-01",{"name":44,"class":45},""]